B 9430 is a potent, selective bradykinin B1/B2 receptor antagonist used in experimental ischemia research. In a gerbil model of global cerebral ischemia, intravenous administration of B 9430 significantly reduced leukocyte rolling along the venular endothelium from 33.0 ± 6.2 to 8.5 ± 2.3 cells per 100 µm × minute, and improved the neuroscore by day 4 from 13.4 ± 3.2 in untreated controls to just 4.7 ± 3.2 points. Despite these marked anti-inflammatory and neuroprotective effects on functional outcome, B 9430 did not prevent neuronal cell death in the cortex, hippocampus, or striatum, making it a valuable tool for dissecting the role of kinin signaling in microcirculatory versus neurodegenerative pathways.